This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

albiglutide (Eperzan®)

Reference No. 855

Publication date:

Appraisal information

albiglutide (Eperzan®) 30 mg powder and solvent for solution for injection
albiglutide (Eperzan®) 50 mg powder and solvent for solution for injection

Company: GlaxoSmithKline
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 24/07/2014

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, albiglutide (Eperzan®) cannot be endorsed for use within NHS Wales for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as: monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance; or add-on combination therapy in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
Statement of Advice (SOA)